PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade
Authors
Keywords
-
Journal
Nature Communications
Volume 11, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-09-24
DOI
10.1038/s41467-020-18570-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A conserved dendritic-cell regulatory program limits antitumour immunity
- (2020) Barbara Maier et al. NATURE
- Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
- (2020) Maud Mayoux et al. Science Translational Medicine
- Visualizing Synaptic Transfer of Tumor Antigens among Dendritic Cells
- (2020) Megan K. Ruhland et al. CANCER CELL
- Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
- (2019) Brian C. Miller et al. NATURE IMMUNOLOGY
- Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses
- (2019) Daisuke Sugiura et al. SCIENCE
- Clonal replacement of tumor-specific T cells following PD-1 blockade
- (2019) Kathryn E. Yost et al. NATURE MEDICINE
- Recruit or Reboot? How Does Anti-PD-1 Therapy Change Tumor-Infiltrating Lymphocytes?
- (2019) Margaret K. Callahan et al. CANCER CELL
- Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade
- (2019) Mohammad Rashidian et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways
- (2019) Yunlong Zhao et al. IMMUNITY
- Distinct contribution of PD-L1 suppression by spatial expression of PD-L1 on tumor and non-tumor cells
- (2018) Xiaoqing Zhang et al. Cellular & Molecular Immunology
- Regulation and Function of the PD-L1 Checkpoint
- (2018) Chong Sun et al. IMMUNITY
- The host protecting the tumor from the host — targeting PD‑L1 expressed by host cells
- (2018) David H. Munn JOURNAL OF CLINICAL INVESTIGATION
- PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression
- (2018) Haidong Tang et al. JOURNAL OF CLINICAL INVESTIGATION
- Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression
- (2018) Heng Lin et al. JOURNAL OF CLINICAL INVESTIGATION
- B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction
- (2018) Ling Chen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells
- (2018) Yunlong Zhao et al. Cell Reports
- PD-L1 binds to B7-1 only in cis on the same cell surface
- (2018) Apoorvi Chaudhri et al. Cancer Immunology Research
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
- (2017) Vikram R. Juneja et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
- (2017) Kenji Chamoto et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
- (2017) Janet Lau et al. Nature Communications
- PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity
- (2017) Maria Gato-Cañas et al. Cell Reports
- Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
- (2017) Takuro Noguchi et al. Cancer Immunology Research
- PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
- (2017) Jan Willem Kleinovink et al. OncoImmunology
- Critical Role for CD103 + /CD141 + Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma
- (2016) Edward W. Roberts et al. CANCER CELL
- Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
- (2016) Haidong Tang et al. CANCER CELL
- Functions of Murine Dendritic Cells
- (2016) Vivek Durai et al. IMMUNITY
- Expansion and Activation of CD103 + Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition
- (2016) Hélène Salmon et al. IMMUNITY
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- Dendritic Cells and Cancer Immunity
- (2016) Alycia Gardner et al. TRENDS IN IMMUNOLOGY
- Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance
- (2016) Wenxin Zheng et al. Oncotarget
- PD-1/PD-L1 inhibitors
- (2015) Joel Sunshine et al. CURRENT OPINION IN PHARMACOLOGY
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- (2015) Stefani Spranger et al. NATURE
- Predictive biomarkers for checkpoints, first tests approved
- (2015) Ken Garber NATURE BIOTECHNOLOGY
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Selective and efficient generation of functional Batf3-dependent CD103+ dendritic cells from mouse bone marrow
- (2014) C. T. Mayer et al. BLOOD
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
- (2013) Joel Crespo et al. CURRENT OPINION IN IMMUNOLOGY
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Ovarian cancer progression is controlled by phenotypic changes in dendritic cells
- (2012) Uciane K. Scarlett et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor-Infiltrating Regulatory Dendritic Cells Inhibit CD8+ T Cell Function via L-Arginine Metabolism
- (2009) L. A. Norian et al. CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started